Day 4 Recap: Fall Clinical 2024

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

Clascoterone, trifarotene, and tazarotene show comparable efficacy in acne vulgaris treatment, as revealed by a recent meta-analysis.
James Song, MD, provided advanced strategies for alopecia areata, refractory dermatoses, and non-steroidal topicals.
Emmy Graber, MD, MBA, highlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill.
Christopher Bunick, MD, PhD, discussed JAK inhibitors and comprehensive treatment targets for atopic dermatitis, referencing AHEAD and LEVEL UP data.
Glynis Ablon, MD, shared top device-based interventions for aesthetic dermatology, enhancing clinical outcomes.

Catch up on coverage from the final day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Study Reveals Comparable Efficacy of Clascoterone, Trifarotene, and Tazarotene in Acne Treatment

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.

James Song, MD, FAAD: Advanced Strategies for Alopecia Areata, Refractory Dermatoses, and Emerging Non-Steroidal Topicals

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

Emmy Graber, MB, MBA, Shares Top Clinical Pearls on Lasers, Erythema Treatments, and Emerging Therapies

At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.

Elevating Standards in Atopic Dermatitis Through JAK Inhibitors and Optimal Treatment Targets

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

Glynis Ablon, MD, Spotlights Top Devices and Innovations in Aesthetic Dermatology

At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.

Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

High Stakes in Dermatology: Jackpot Insights from Fall Clinical 2024

Discover top innovations, insights, and clinical pearls from Fall Clinical in Las Vegas, where dermatology’s biggest breakthroughs took center stage.

To view all conference coverage from Fall Clinical 2024, click here.